Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …

CD8+ T cell responses are critical for anti-tumor immunity. While extensively profiled in the
tumor microenvironment, recent studies in mice identified responses in lymph nodes (LNs) …

Improvements in tumor immunotherapies depend on better understanding of the anti-tumor
T cell response. By studying human tumor-draining lymph nodes (TDLNs), we found that …

Immune-checkpoint blockade (ICB) therapies represent a paradigm shift in the treatment of
human cancers; however, it remains incompletely understood how tumor-reactive T cells …

Summary Blocking PD-1/PD-L1 signaling transforms cancer therapy and is assumed to
unleash exhausted tumor-reactive CD8+ T cells in the tumor microenvironment (TME) …

CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Virus-specific CD8+ T cells that differentiate in the context of resolved versus persisting
infections exhibit divergent phenotypic and functional characteristics, which suggests that …

Summary CD4 T follicular helper (TFH) cells support B cells, which are critical for germinal
center (GC) formation, but the importance of TFH-B cell interactions in cancer is unclear. We …

Antigen-specific CD8+ T cell accumulation in tumors is a prerequisite for effective
immunotherapy, and yet the mechanisms of lymphocyte transit are not well defined. Here we …